The Ministry of Health and Prevention (MoHAP) in the UAE has withdrawn batch number ME051 of the API Sinocort Nasal Spray, a medication that's used to treat asthma and blocked airways.
The spray is manufactured by Amman Jordan Pharmaceutical Industries.
In a statement, MoHAP said the decision was made after a review of the batch showed it had failed to conform to the approved specifications.
Pharmacists and healthcare providers have been ordered to withdraw it from sale and return the drug to the suppliers
Users are advised to dispose of the batch and report any adverse reactions.
Dr. Amin Hussein Al Amiri, Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, and Chairman of the Supreme National Committee for Pharmacovigilance, urged people to contact them by email at ph@moh.gov.ae, through the E-system on MoHAP’s website, or the smart app ‘UAE RADAR.’
Sheikh Mansour, Iranian Parliament Speaker discuss regional de-escalation
Sharjah private schools, nurseries staff resume in-person work
Dubai and Sharjah early childhood centres set for gradual re-opening
UAE President, European Council chief discuss regional developments
New batch of Indonesian medical team joins UAE Floating Hospital
